ArticleAddictive behaviors2023
Adult use of highly-potent Δ9-THC cannabis concentrate products by U.S. state cannabis legalization status, 2021.
Article in Addictive behaviors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- High-Potency Cannabis Use and Health: A Systematic Review of Observational and Experimental Studies.The American journal of psychiatry · 2025Pooled it
- Randomized Laboratory Study of Single-Dose Cannabis, Dronabinol, and Placebo in Patients With Schizophrenia and Cannabis Use Disorder.Schizophrenia bulletin · 2025Trial
- Gimmie the Gummies: Initial validation of the Edibles Marijuana Purchase Task.Experimental and clinical psychopharmacology · 2026Article
- Bedtime tetrahydrocannabinol ingestion reduces morning orthostatic cardiovascular reactivity in adults: An exploratory study.Physiological reports · 2026Article
- Emergency department use by individuals with and without psychosis after state-level cannabis legalization and commercialization.Nature. Mental health · 2026Article
- A cross-sectional analysis of Behavioral Risk Factor Surveillance System (BRFSS) data to determine if tobacco and cannabis methods of administration are likely to be consistent across products.Respiratory research · 2026Article
- Centering Individuals With Mental Illness as an At-Risk Group in the Era of Cannabis Legalization and Commercialization.Clinical therapeutics · 2026Article
- Cannabis Use Among Individuals With Psychosis After State-Level Commercial Cannabis Legalization.JAMA psychiatry · 2026Article
- United States healthcare encounters for poisoning involving cannabis relative to other substances.The American journal of drug and alcohol abuse · 2026Article
- Labeling of Cannabis Products From Licensed and Unlicensed Retailers in New York.American journal of preventive medicine · 2025Article
- Event-Level Differences in Quantity, Frequency, and Consequences of Cannabis Use by Modes of Use Among Sexual Minority Women and Gender Diverse Individuals.Journal of studies on alcohol and drugs · 2025Article
- Age Differences in Cannabis Consumption Patterns and in Associations Between Delta-9-Tetrahydrocannabinol Intake and Cannabis Use Disorders Among Adults with Daily Use.Cannabis and cannabinoid research · 2025Article
- Tetrahydrocannabinol vape-associated cannabis arteritis in a patient with minimal tobacco exposure.Journal of vascular surgery cases and innovative techniques · 2025Article
- Unmet Healthcare Needs and Medical Cannabis Use Among Sexual and Gender Minoritized Adults in a High-Stigma Environment.Journal of homosexuality · 2025Article
- The Longitudinal Association of Cumulative Depression With Cannabis Use Disorder Among Young Adults.Journal of studies on alcohol and drugs · 2025Article
- Evolution of the substance use landscape: Implications for contingency management.Journal of applied behavior analysis · 2025Review
- Nicotine and cannabis routes of administration and dual use among U.S. young adults who identify as Hispanic, non-Hispanic Black, and non-Hispanic White.Preventive medicine reports · 2024Article
- Products and patterns through which adolescents, young adults, and adults initiate co-use of tobacco and cannabis.Addictive behaviors · 2024Article
- Regulatory Landscape of Cannabis Warning Labels in US States with Legal Retail Nonmedical Cannabis, 2024.American journal of public health · 2024Article
- Disproportionate increase in cannabis use among people with serious psychological distress and associations with psychiatric service use in the United States, 2009-2019.Addictive behaviors · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundCompared to plant/flower cannabis products, cannabis concentrates have higher average potency of delta-9-tetrahydrocannabinol (Δ9-THC), which may be associated with greater likelihood of cannabis-related harms. Information on factors associated with use of cannabis concentrates is needed.
methodsRespondents were 4,328 adult past-7-day cannabis users from all 50 U.S. states and Washington DC (DC) who participated in an online 2021 survey. Using logistic regression to generate adjusted odds ratios (aOR), we investigated whether participants in states that enacted recreational cannabis laws (RCL, 12 states plus DC [treated as a state], n = 1,236) or medical cannabis laws (MCL-only, 23 states, n = 2,030) by December 31, 2020 were more likely than those in states without cannabis laws (no-CL, 15 states, n = 1,062) to use cannabis concentrate products in the prior 7 days.
resultsMost participants (92.4%) used plant material in the prior 7 days; 57.0% used cannabis concentrates. In RCL, MCL and no-CL states, concentrate use was reported by 61.5%, 56.6%, and 52.5%, respectively. Compared to participants in no-CL states, odds of using cannabis concentrate products were greater among those in RCL states (aOR = 1.47; CI = 1.17-1.84) and MCL-only states (aOR = 1.29; CI = 1.08-1.55). Whether states had legally-authorized dispensaries had little effect on results.
conclusionResults suggest that individuals in MCL-only and RCL states are more likely to use cannabis concentrate products. Determining mechanisms underlying these results, e.g., commercialization, could provide important information for prevention. Clinicians should be alert to patient use of concentrates, especially in MCL-only and RCL states. Continued monitoring is warranted as additional states legalize cannabis use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.